An Introduction to the Biopharmaceutical Industry
The Chemical Engineering magazine has published an overview of the biopharmaceutical industry written by Merck/MilliporeSigma employees. This article highlights the role of chemical engineers, and sets the stage for subsequent articles that will explore additional aspects of the industry leading the charge in the battle against the pandemic. The series will provide a behind-the-scenes look into the products, key unit operations, required skillsets, and the future of the industry.
Read the first article of the series “An introduction to the biopharmaceutical industry” and enter the fascinating biotech world.
https://www.thechemicalengineer.com/features/an-introduction-to-the-biopharmaceutical-industry/
David Gemmell has been working for Merck/MilliporeSigma for over six years. David is currently employed with the Technical & Scientific Solutions MSAT (Manufacturing Sciences & Technology) department. David’s primary focus is on optimising or troubleshooting downstream purification unit operations for customers, focusing on both novel and traditional modalities, across all purification technologies. He is also the High Temperature Short Time Subject Matter Expert for upstream viral risk mitigation. At University David obtained a BEng (Hons) in Chemical Engineering and an MSc in Advanced Chemical & Process Engineering. His early career was based in the nuclear and power generation sectors before moving into biopharmaceutical and life sciences.
Latest posts by David Gemmell (see all)
